ABSTRACT Background. The ACOSOG Z0011 trial demonstrated that axillary dissection (ALND) is not necessary for local control or survival in women with T1/2cN0 cancer undergoing breast-conserving therapy. There is concern about applying these results to triple-negative (TN) cancers secondary to their high local-recurrence (LR) rate. We examined the frequency of lymphovascular invasion (LVI) and nodal metastases in TN cancers to determine whether ALND can be safely avoided in this subtype.
Gene expression profiling has established that breast cancer comprises a group of biologically distinct diseases. 1, 2 Expression levels of the estrogen receptor (ER) and progesterone receptor (PR), together defining hormone receptor (HR) status, and the HER2/neu receptor (HER2), characterize clinical surrogates for the molecular subtypes of breast cancer: HR?/HER2-(luminal A-like); HR?/ HER2? (luminal B-like); HR-/HER2? (HER2 tumors); and HR-/HER2-(triple-negative [TN] , also referred to as basal-like). 3 Expression of these receptors can be measured by immunohistochemistry (IHC), allowing subtype classification to be widely applied in the clinical setting. This information is used to guide systemic therapy and to predict response to treatment and prognosis. [4] [5] [6] [7] [8] Patterns of recurrence and outcome differ among breast cancer molecular subtypes. [8] [9] [10] HER2 tumors, before the use of adjuvant trastuzumab, and TN tumors were associated with higher local recurrence (LR) rates and poorer overall survival (OS) than HR-positive tumors. 9, 10 With the increased use of trastuzumab in the treatment of HER2-overexpressing breast cancer (including the HR?/HER2? and HR-/HER2? subtypes), the rates of local failure and prognosis in this group have improved significantly, while TN breast cancers continue to have a poor prognosis and an increased rate of LR. 11 Given this, there is concern about adopting any treatment strategy with less aggressive local management for patients with TN breast cancers. In particular, there is concern about applying results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial, which demonstrated that axillary lymph node dissection (ALND) is not necessary for locoregional control or survival in women with T1/2cN0 cancer undergoing breastconserving therapy (BCT) because relatively few women with HR-negative tumors were included in this study and HER2 status was unknown. 12, 13 Here we sought to quantify the frequency of lymphovascular invasion (LVI) and nodal metastases in each breast cancer subtype as approximated by ER, PR, and HER2, and to determine whether TN tumors have a higher risk of LVI and nodal metastases in case this risk should preclude the application of ACOSOG Z0011 to this subtype.
METHODS

Patient Population
A total of 11,449 patients with 11,715 invasive breast cancers were treated at Memorial Sloan Kettering Cancer Center (MSKCC) between January 1998 and December 2010. Of these, ER, PR, and HER2 status was available in all but 119 tumors, in which the HER2 status was equivocal, leaving 11,596 tumors that were classifiable into surrogates for molecular subtype on the basis of their biomarker profiles. Patients with prior malignancy were included as long as their breast cancer was a primary breast cancer. In patients who had bilateral breast cancers, each cancer was included as a separate event and its biomarker profile recorded. Patients who were treated with neoadjuvant systemic therapy were excluded. Data were obtained from a prospectively maintained registered database. This study was approved by the MSKCC institutional review board.
Classification of Groups
Tumors were classified as follows: HR?/HER2-(ER? or PR? and HER2-), HR?/HER2? (ER? or PR? and HER2?), HR-/HER2? (ER-and PR-and HER2?), and TN HR-/HER2-(ER-and PR-and HER2-). ER and PR status was determined by IHC. ER and PR positivity was defined as the presence of staining of C1 % of tumor cells. Tumors were considered HER2? if they scored ''3?'' by IHC or if they were HER2 amplified (ratio C 2.2) on the basis of fluorescence in-situ hybridization. Grade was defined as nuclear grade when available. When nuclear grade was not available or reported, histologic grade was used as a surrogate. If the histology was compatible with classic lobular carcinoma, the tumor was assigned ''low'' grade. Nodal positivity was defined as the presence of any tumor cells in a lymph node and included macrometastases, micrometastases, and isolated tumor cells.
Statistical Analysis
The v 2 test was used for categorical variables and analysis of variance for continuous variables to compare the distribution of clinicopathologic characteristics among the four subtypes. All percentages and statistical tests were based on available data. Multivariable logistic regression analysis (MVA) was used to examine whether subtype was independently associated with three outcomes of interest: LVI; any nodal involvement; and high-volume nodal involvement. All models were adjusted for tumor size (continuous), grade (high vs. intermediate/low), age (at time of surgery, continuous), and for the two nodal involvement models considered, LVI. TN was the reference group. Patients with missing covariate data (n = 571) were excluded from the MVA. All statistical tests were two sided, and a p value of B0.05 was considered significant. All statistical analyses were performed by SAS software, version 0.1 (SAS Institute, Cary, NC).
RESULTS
The distribution of subtype in the study population was 74 % HR?/HER2-, 8 % HR?/HER2?, 5 % HR-/ HER2?, and 13 % TN. The presenting characteristics of the entire population are summarized in Table 1 . Patient and tumor characteristics divided by subtype are displayed in Table 2 . Among the four subtypes, there were significant differences in age, tumor size, LVI, grade, and nodal involvement (all p \ 0.0001). Patients with HR?/HER2-tumors presented at an older median age than the other subtypes with a median age of 57.5 (range 22-96) years. HR-/HER2? and TN tumors were larger and more frequently high grade than the HR? tumors. 25 % of HR?/ HER2-tumors were high grade compared with 89 and 86 % of HR-/HER2? and TN tumors, respectively. On univariate analysis, HR?/HER2-and TN tumors had lower rates of LVI than the HER2 overexpressing subtypes. HR?/HER2-and TN tumors were also less likely to have C1 lymph node involved and to have high-volume lymph node involvement (C4 nodes involved) than HER2 overexpressing tumors.
On MVA, after controlling for tumor size, grade, and age, subtype was independently associated with LVI (p \ 0.0001) (Table 3) . Specifically, patients with the TN subtype had the lowest odds of demonstrating LVI, with patients with the HR?/HER2? subtype being 2.5 times more likely than those with the TN subtype to have LVI [odds ratio (OR), 2.5; 95 % confidence interval (CI), 2.0-3.0]. Patients with the HR?/HER2-subtype were 80 % more likely (OR 1.8; 95 % CI 1.6-2.1) and patients with HR-/HER2? were 70 % more likely (OR 1.7; 95 % CI 1.4-2.1) to have LVI than those with the TN subtype.
On MVA, after controlling for tumor size, grade, LVI, and age, subtype was independently associated with any lymph node involvement and high-volume lymph node involvement (C4 lymph nodes involved, p \ 0.0001) (Table 4) . Specifically, patients with the HR-/HER2-subtype had the lowest odds of having C1 positive node and of having high-volume lymph node involvement. HR-/HER2? tumors were 2.0 times more likely than HR-/HER2-tumors to be associated with any nodal involvement (OR 2.0; 95 % CI 1.6-2.5) and were 2.3 times more likely than HR-/HER2-tumors to have C4 nodes involved (OR 2.3; 95 % CI 1.7-3.1). 
DISCUSSION
Our study confirms and expands on our previous work indicating that presenting tumor features vary by breast cancer molecular subtype approximated by ER, PR, and HER2 status.
14 These features include age, tumor size, LVI, grade, and nodal involvement. The previous study by Wiechmann et al. included 6,072 breast tumors (the majority of which are included in the current study) and showed that TN tumors had the lowest risk of having any nodal disease and high-volume nodal disease. This observation is consistent with several published series relating these characteristics to molecular subtype. Crabb et al. 15 demonstrated in a retrospective analysis of 3,441 earlystage breast cancers that subtype as approximated by ER, PR, and HER2 was predictive of nodal involvement, independent of grade and tumor size. The TN subtype had the lowest odds of having axillary lymph node involvement, with an OR of 0.53 (95 % CI 0.41-0.6; p \ 0.0001) relative to the HR?/HER2-subtype. The current study, which includes 11,596 breast cancers and expands our group of TN cancers to 1517, represents the largest series classified by subtype and analyzed for features of lymphatic invasion and nodal involvement to the best of our knowledge. An additional finding in the current analysis is that TN tumors also have the lowest rate of LVI of all subtypes. To our knowledge, this has not been previously demonstrated in any large series.
The finding of a low incidence of LVI calls into question the means through which TN tumors express their aggressive phenotype. Several studies link TN tumors to a high risk of LR and poor survival. 10, 16, 17 Nguyen et al. 8 studied 793 patients with invasive breast cancer and clinically approximated molecular subtype and found that the 5-year cumulative incidence of LR was 7.1 % for the TN tumor group and 8.4 % for the HR-/HER2? group compared with 0.8 and 1.5 % for the HR?/HER2-and HR?/ HER2? groups, respectively. Lowery et al. 9 quantified the influence of subtype on locoregional recurrence after BCT and mastectomy by performing a meta-analysis of 12,592 patients. They found HR? tumors had a lower risk of LR than TN (risk ratio 0.38; 95 % CI 0.23-0.61) and HER2 tumors (risk ratio 0.34; 95 % CI 0.26-0.45) after BCT. After mastectomy, HR? tumors had a lower risk of LR than TN (OR 0.61; 95 % CI 0.46-0.79) and HER2 tumors (OR 0.69; 95 % CI 0.54-0.89). HER2 tumors had a higher risk of LR than TN tumors after BCT, but there was no difference between HER2 and TN tumors after mastectomy. Adjuvant trastuzumab was not used in the studies included in this analysis, and it is likely that since trastuzumab decreases LR in HER2 overexpressing breast cancer, TN tumors would be associated with the highest risk of LR if patients treated with more modern regimens were included in the analysis. 11 A retrospective analysis of two prospective clinical trials performed by the Danish Breast Cancer Cooperative Group showed a significant improvement in OS in patients with HR? and HER2-tumors that were treated with postmastectomy radiotherapy but no significant improvement in patients with TN cancers or HER2-overexpressing cancers before the use of trastuzumab. Smaller reductions in locoregional recurrence after PMRT were also seen in TN and HR-/ HER2? patients compared with those with HR?/HER2-tumors. In contrast to the increased rates of in breast recurrence and postmastectomy chest wall recurrence reported for TN cancers, evidence that rates of nodal recurrence are increased is lacking. For instance, the ACOSOG Z0011 trial demonstrated that among patients with limited sentinel lymph node (SLN) metastases undergoing BCT, SLN biopsy alone resulted in rates of locoregional recurrence, disease-free survival (DFS), and OS similar to ALND but with decreased morbidity. 12, 13 This was attributed to the effectiveness of the radiation therapy and systemic therapy (given to over 95 % of patients) at reducing locoregional recurrence. Of the patients randomized into ACOSOG Z0011, 83 % were ER positive. HER2 status was not routinely determined during the time period of that study, raising concerns about the applicability of the results to TN breast cancers. No differences in DFS or OS were noted on the basis of HR status, and the number of regional failures was too small to analyze on the basis of HR status. 19 Dengel et al. 20 analyzed 287 patients who met ACO-SOG Z0011 eligibility criteria and were treated with SLN biopsy alone if metastases were present in \3 sentinel nodes and gross extracapsular extension was not identified intraoperatively. Eighty-four percent of patients met indications for SLN biopsy alone and avoided ALND. The study demonstrated that age, HR status, HER2 status, and grade did not differ between the SLN biopsy-only and ALND groups (p \ 0.0001). Our study provides further reassurance that application of the ACOSOG Z0011 findings to patients with TN breast cancer is appropriate by demonstrating that they are actually less likely to have a heavy nodal disease burden than patients with other tumor subtypes. This conclusion is further supported by two large studies specifically examining predictors of nodal recurrence in patients undergoing ALND. Grills et al. 21 and Yates et al. 22 examined predictors of nodal recurrence in multivariate models which included HR status in 1,500 and 1,065 patients, respectively. In neither study was HR status found to be significant. In aggregate, the literature and the current study do not suggest a propensity for heavy nodal disease burden or an increased risk of isolated nodal recurrence in TN patients, and we routinely perform SLN biopsy alone in patients meeting ACOSOG Z0011 eligibility criteria, regardless of HR and HER2 status. Thus the elevated rates of locoregional recurrence reported for TN cancer likely reflects the excess of in-breast and chest wall recurrences in these patients.
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Our study confirms the results of other studies indicating that presence of LVI is associated with an increased risk of nodal involvement (Table 4) . 15, [23] [24] [25] [26] [27] When LVI was absent, the risk of any nodal involvement was 0.28 (95 % CI 0.26-0.31) compared with when it was present. Additionally, LVI is well documented to be a risk factor for LR after both BCT and mastectomy, raising the possibility that an increased frequency of LVI could be responsible for the higher rates of LR in the breast and chest wall seen with TN breast cancer. [28] [29] [30] However, we found that of all the subtypes, TN cancers were least likely to have LVI.
A question that remains unanswered is the means through which TN breast cancers achieve their higher rate of LR. The findings of our study suggest that high-risk features of the primary tumor are unlikely to be the explanation. An alternative explanation is the lack of targeted therapy. The dramatic effect of targeted therapy on local outcomes is illustrated by the decrease in locoregional recurrence seen in HER2 overexpressing patients with the addition of trastuzumab to chemotherapy after both BCT and mastectomy. Kiess et al. 31 reported that rates of locoregional recurrence at 3 years after BCT decreased from 7 to 1 % with the addition of trastuzumab treatment, and a similar reduction was seen in patients undergoing mastectomy. 32 The benefit of endocrine therapy in reducing LR is well documented, with a 50 % reduction in locoregional recurrence after 5 years of tamoxifen compared with placebo, with additional incremental benefit observed with the use of the aromatase inhibitors or switching strategies. 33, 34 The hypothesis that features of the primary tumor are unlikely to be responsible for the increased rates of LR seen in TN breast cancer is further supported by observations that larger surgical procedures do not improve outcomes in TN breast cancer. Pilewskie et al. 35 demonstrated that margins [2 mm do not decrease LR compared with margins \2 mm in size in TN patients undergoing BCT, and three retrospective studies have failed to demonstrate that mastectomy improves local control compared with BCT. 28, 36, 37 Strengths of our study include its large size and the performance of ER, PR, and HER2 testing in a single pathology laboratory. However, there are several potential limitations to this study. First, the data used in this study are retrospective, although this is unlikely to influence the ascertainment of nodal metastases. Second, classification of subtype was based on IHC, which only approximates the genotype-based breast cancer subtype, such that there may be some level of misclassification of tumors. 38, 39 However, at this time, IHC surrogates are used for clinical decision making, so this approach provides information relevant to patient care. [4] [5] [6] 8 In summary, our study demonstrates that TN tumors have the lowest risk of any subtype of having LVI or LN metastases, despite the uniformly worse prognosis and increased rate of LR in these tumors. This implies the mode of recurrence of TN tumors is not driven by lymphatic invasion. We believe that among patients with early TN tumors and limited SLN metastatic breast cancer, treatment with BCT and SLNB alone, and not ALND, according to the ACOSOG Z0011 trial results, is adequate and safe, and reduces morbidity.
